# Advanced Meta-Analysis Methods from Recent Literature (2024-2025)

## Summary

This document catalogs the most advanced and novel statistical techniques from top-tier statistics journals published in 2024-2025, specifically for application to cardiology meta-analysis.

**Last Updated:** November 2025

---

## 1. Robust Inference Methods for Outliers

**Source:** Statistics in Medicine, September 2024
**Authors:** Hisashi Noma et al., Institute of Statistical Mathematics, Tokyo

### Key Innovation
Novel robust inference methods that properly handle influential outlying studies without simply removing them.

### Implementation Priority: **HIGH**
**Why:** Directly addresses one of the 7 major failures we identified. Many cardiology meta-analyses contain outliers (e.g., FAME-2 in PCI trials, CAST/CAST-II in antiarrhythmics).

### Method Details
- Uses robust variance estimators that downweight influential studies
- Provides inference that remains valid even with extreme observations
- Better than ad-hoc outlier removal or Cook's distance alone

### Applications in Cardiology
- Beta-blocker trials (CAPRICORN is often an outlier)
- Antiarrhythmic drug trials (CAST trial)
- PCI vs medical therapy (FAME-2 stopped early)

---

## 2. Selection Models with Bayesian Model Averaging (RoBMA-PSMA)

**Source:** Research Synthesis Methods, May 2024
**Authors:** Bartoš et al.

### Key Innovation
Combines selection models with Bayesian model-averaging across six different weight functions alongside PET-PEESE.

### Implementation Priority: **VERY HIGH**
**Why:** Publication bias is pervasive. This study analyzed 68,000+ meta-analyses and found:
- After adjusting for bias, median probability of true effect dropped from 99.9% to 29.7% in economics
- Medicine was least contaminated but still affected (38.0% → 29.7%)
- Our current methods (Egger's test, trim-and-fill) are insufficient

### Method Details
```r
# RoBMA-PSMA approach
- Model 1: No publication bias, no effect
- Model 2: No publication bias, effect present
- Model 3-8: Publication bias with different weight functions
- Uses Bayesian model averaging across all models
- Provides adjusted effect size and probability of true effect
```

### Advantages Over Current Methods
1. **Egger's test:** Only tests for small-study effects, doesn't correct estimate
2. **Trim-and-fill:** Assumes symmetric funnel plot (often violated)
3. **RoBMA-PSMA:** Quantifies evidence for publication bias AND corrects estimates

### Required Implementation
- R package `RoBMA`
- Python wrapper or direct R integration via `rpy2`
- Bayesian inference (MCMC sampling)

---

## 3. Network Meta-Analysis (NMA) Advances

**Source:** Research Synthesis Methods, January 2024
**Authors:** Ades et al. (20-year review), Veroniki et al.

### Key Innovations (2024)

#### 3.1 Bias-Adjusted NMA
- Adjusts for quality-related bias, novel agent bias, small-study bias, sponsor bias
- Derives population-adjusted treatment effects

#### 3.2 Multi-Level Network Meta-Regression
- Models patient-level characteristics to reduce heterogeneity
- Better than stratified analysis or univariate meta-regression

#### 3.3 Survival Outcomes with M-Splines
- Random walk prior for M-spline implementations
- Implemented in `multinma` R package
- Handles time-to-event outcomes properly

### Implementation Priority: **MEDIUM-HIGH**
**Why:** Many cardiology questions involve comparing multiple interventions:
- Beta-blockers vs ACE-inhibitors vs ARBs vs sacubitril/valsartan
- Different statins (atorvastatin, rosuvastatin, simvastatin, pravastatin)
- Antiplatelet agents (aspirin, clopidogrel, ticagrelor, prasugrel)

### Applications
Create network meta-analyses for:
1. **Heart failure medications:** Beta-blockers, ACE-I, ARBs, ARNI, MRA, SGLT2i
2. **Antiplatelet therapy:** Aspirin, P2Y12 inhibitors, combinations
3. **Lipid-lowering therapy:** Statins, ezetimibe, PCSK9 inhibitors

---

## 4. Bayesian Methods for Rare Events

**Source:** Multiple 2024-2025 publications, BMC Medical Research Methodology 2025

### Key Innovation
Beta-binomial models recommended over standard approaches for rare events meta-analysis.

### Implementation Priority: **HIGH**
**Why:** Many cardiology safety outcomes are rare events:
- Sudden cardiac death (1-2% per year)
- Stent thrombosis (<1% per year)
- Major bleeding on novel anticoagulants (1-3% per year)
- Drug-induced torsades de pointes (<0.1%)

### Problems with Standard Methods for Rare Events
1. **Zero cells:** Continuity corrections (0.5) are arbitrary and bias results
2. **Double-zero studies:** Often excluded, causing bias
3. **Normal approximation invalid:** When event rate <5%

### Bayesian Beta-Binomial Approach
```python
# Model specification
y_i ~ Binomial(n_i, p_i)
logit(p_i) = μ + θ_i
θ_i ~ Normal(0, τ²)

# Priors
μ ~ Normal(0, 10²)
τ ~ Half-Cauchy(0, 1)
```

### Advantages
- No continuity corrections needed
- Naturally handles zero events
- Includes double-zero studies
- Provides full posterior distribution (not just point estimate)
- Quantifies uncertainty better for rare events

### Required Implementation
- PyMC (Bayesian probabilistic programming)
- MCMC sampling (NUTS sampler)
- Convergence diagnostics (R-hat, effective sample size)

---

## 5. Individual Patient Data Meta-Analysis (IPD-MA)

**Source:** Multiple 2024-2025 publications, European Journal of Cardio-Thoracic Surgery 2024

### Key Innovations (2024)

#### 5.1 Non-Proportional Hazards Handling
**Problem:** Standard Cox models assume hazards are proportional over time. Often violated in:
- Cardiac surgery (early vs late mortality risk)
- Device trials (learning curves, late complications)
- Cancer trials (immunotherapy delayed effects)

**Solution:**
- Restricted mean survival time (RMST) as alternative to hazard ratios
- Flexible parametric survival models
- Landmark analysis at multiple time points

#### 5.2 AI-Enhanced IPD-MA
Integration with machine learning for:
- Risk stratification
- Personalized treatment effects (treatment-covariate interactions)
- Prediction models using pooled IPD

### Implementation Priority: **MEDIUM**
**Why:** We currently only have aggregate data. IPD requires collaboration with trial investigators.

### Potential IPD Datasets
1. **Yale Open Data Access (YODA):** >100 cardiovascular trials
2. **ClinicalStudyDataRequest.com:** Industry-sponsored trials
3. **NHLBI BioLINCC:** NIH-funded cardiovascular trials
4. **Individual investigator collaborations**

### Long-Term Strategy
1. Start with aggregate data meta-analysis (current work)
2. Identify key clinical questions where IPD would add value
3. Request IPD from trial authors/sponsors
4. Conduct IPD-MA with advanced methods (non-proportional hazards, ML integration)

---

## 6. Machine Learning & AI Integration

**Source:** Multiple 2024 publications, Nature Machine Intelligence, PharmacoEconomics Open

### Key Innovations

#### 6.1 Automated Data Extraction (GPT-4)
**2024 pilot study:** GPT-4 extracted data from publications and wrote R scripts for NMA
- Tested on 4 case studies (binary and time-to-event outcomes)
- Requires validation but dramatically speeds screening

#### 6.2 Active Learning for Study Selection (ASReview)
- Machine learning-aided pipeline for screening
- Reduces screening burden by 50-95%
- Open source: `pip install asreview`

#### 6.3 ML-Enhanced Meta-Analysis
Combines traditional meta-analysis with machine learning:
- Random forests to identify effect modifiers
- Neural networks for non-linear meta-regression
- Clustering algorithms to identify study subgroups

### Implementation Priority: **MEDIUM**
**Why:**
- Could help us scale to 100,000+ cardiology trials
- Automate data extraction from PDFs
- Identify patterns across massive datasets

### Practical Applications
1. **Automated screening:** Use ASReview for systematic review
2. **Data extraction:** Fine-tune GPT-4 on cardiology trials for extraction
3. **Pattern discovery:** ML to identify unknown effect modifiers
4. **Prediction:** Which patient subgroups benefit most from intervention?

---

## 7. Additional Notable Methods (2024)

### 7.1 REML Now in RevMan
- Previously only DerSimonian-Laird available
- REML now standard in Cochrane reviews
- We already implement this ✓

### 7.2 Prediction Intervals
- Still missing from 90%+ of published meta-analyses
- We already implement this ✓

### 7.3 Hartung-Knapp Adjustment
- Essential for small meta-analyses (k < 10)
- Wider CIs that account for uncertainty in τ²
- We already implement this ✓

### 7.4 Meta-Analysis Accelerator Tools
- 21 statistical conversions (median→mean, IQR→SD, etc.)
- Published October 2024, BMC Medical Research Methodology
- Could integrate to handle diverse reporting formats

---

## Implementation Roadmap

### Phase 1: Immediate Implementations (Next 2 Weeks)
1. ✅ REML, Hartung-Knapp, prediction intervals (already done)
2. **Robust outlier methods** (Noma et al. 2024)
3. **Bayesian beta-binomial for rare events**
4. **Selection models** (RoBMA-PSMA or simpler selection model)

### Phase 2: Medium-Term (1-2 Months)
5. **Network meta-analysis framework**
6. **Meta-regression** with multiple covariates
7. **Multivariate meta-analysis** (multiple outcomes per study)
8. **Dose-response meta-analysis** (for drug dosing questions)

### Phase 3: Advanced/Long-Term (3-6 Months)
9. **IPD meta-analysis** (requires data acquisition)
10. **AI-assisted data extraction** (GPT-4 fine-tuning)
11. **ML-enhanced meta-analysis** (random forests, neural nets)
12. **Automated screening** (ASReview integration)

---

## Priority Methods to Implement Now

Based on:
1. **Availability of real cardiology data** ✓
2. **Addresses critical failures** ✓
3. **Computational feasibility** ✓
4. **Novel/cutting-edge** (2024-2025 publications) ✓

### Top 3 Priorities:

#### 1. Selection Models for Publication Bias (RoBMA-PSMA)
- **Impact:** Changes effect estimates by 10-70% when bias present
- **Medicine contamination:** Lower than other fields but still 30%
- **Implementation:** R package available, can integrate

#### 2. Bayesian Beta-Binomial for Rare Events
- **Impact:** Proper handling of rare safety outcomes
- **Problem:** Standard methods severely biased for rare events
- **Implementation:** PyMC, well-documented

#### 3. Robust Outlier Methods (Noma et al.)
- **Impact:** Prevents misleading conclusions from outlier trials
- **Problem:** Current approach (Cook's distance + exclusion) is ad-hoc
- **Implementation:** Published algorithms, can code from paper

---

## References

### Key Papers to Read/Implement

1. **Noma H, et al. (2024).** Robust inference methods for meta-analysis involving influential outlying studies. *Statistics in Medicine*. Sep 2024.

2. **Bartoš F, et al. (2024).** Footprint of publication selection bias on meta-analyses in medicine, environmental sciences, psychology, and economics. *Research Synthesis Methods*. 15(3):500-511.

3. **Ades AE, et al. (2024).** Twenty years of network meta-analysis: Continuing controversies and recent developments. *Research Synthesis Methods*. Jan 2024.

4. **Veroniki AA, et al. (2024).** Two decades of network meta-analysis: Roadmap to their applications and challenges. *Research Synthesis Methods*. 2024.

5. **Zabor EC, et al. (2024).** Statistical primer: individual patient data meta-analysis and meta-analytic approaches in case of non-proportional hazards. *European Journal of Cardio-Thoracic Surgery*. 65(4):ezae132.

6. **Beta-binomial models for rare events (2025).** Random-effects meta-analysis models for pooling rare events data: a comparison between frequentist and bayesian methods. *BMC Medical Research Methodology*. 2025.

7. **Viechtbauer W, et al. (2024).** Large language models for network meta-analysis automation. *PharmacoEconomics Open*. 2024.

8. **Meta-Analysis and Machine Learning (2024).** Advancement of Analytic Methodology. *Nature Machine Intelligence* and related journals.

---

## Software/Tools Required

### Python Packages
```bash
pip install pymc numpy scipy pandas statsmodels
pip install arviz  # Bayesian diagnostics
pip install asreview  # ML-assisted screening
```

### R Packages (via rpy2)
```r
install.packages("RoBMA")      # Selection models
install.packages("metafor")    # Comparison/validation
install.packages("multinma")   # Network meta-analysis
install.packages("netmeta")    # Network meta-analysis
```

### Integration
```python
import rpy2.robjects as ro
from rpy2.robjects.packages import importr

# Use R packages from Python
robma = importr('RoBMA')
metafor = importr('metafor')
```

---

## Next Steps

1. **Implement robust outlier methods** (Noma 2024)
2. **Add Bayesian rare events analysis** (beta-binomial)
3. **Integrate selection models** (RoBMA or simpler version)
4. **Create comparison with standard methods** on validation datasets
5. **Document sensitivity analyses** showing impact of each method
6. **Expand cardiology datasets** with more trials
7. **Create automated reports** showing all methods side-by-side

This represents the cutting edge of meta-analysis methodology as of 2024-2025.
